Stock Monitor: Amedica Post Earnings Reporting
LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors issued a free report on Hologic, Inc. (NASDAQ: HOLX), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=HOLX as the Company's latest news hit the wire. On November 24, 2017, the Company declared that it has received the 510(k) clearance from the US Food and Drug Administration (FDA) for its Quantra™ 2.2 Breast Density Assessment Software. The Quantra™ software helps clinicians provide appropriate treatment to women through consistent breast density assessments during routine breast cancer screenings. Sign up now for our free research reports at: www.active-investors.com/registration-sg.
Active-Investors.com is currently working on the research report for Amedica Corporation (NASDAQ: AMDA ), which also belongs to the Healthcare sector as the Company Hologic. Do not miss out, become a member today for free to access this upcoming report at: www.active-investors.com/registration-sg/?symbol=AMDA.
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Hologic most recent news is on our radar and we have decided to include it in our blog post. Today's free coverage is available at: www.active-investors.com/registration-sg/?symbol=HOLX.
The Quantra™ software is being demonstrated at the 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which is being held at McCormick Place in Chicago from November 26 to November 30, 2017.
About the Quantra™ Software
Quantra™ 2.2 Breast Density Assessment Software runs through a proprietary algorithm powered by machine learning. It provides clinicians patient-specific breast density assessment by analyzing mammography images for distribution and texture of breast tissue. The software classifies breasts into four categories of density, in alignment with the ACR BI-RADS® Atlas 5th Edition.
Benefits to Patients and Clinicians
It is difficult to detect breast cancer during annual screenings in case of women with dense breasts. About 50% of the women in the age group of 40 to 74 years are said to have dense breasts. Difficulty in detecting cancer leads to repetitive imaging, which results in increased patient anxiety and unnecessary facility costs. In fact, women with very dense breasts are four to five times more likely to develop breast cancer than women with less dense breasts.
Breast density can be identified on a mammogram or other screening modality, which is mostly determined by the radiologist who reads the image. The Quantra™ software helps ensure clinicians that they are providing their patients with an unbiased breast density assessment that removes the possibility of any visual subjectivity.
Software Compatible with Hologic's Genius 3D Mammography
The Quantra™ software can be used with Hologic's (NASDAQ: HOLX) 3D Mammography systems, including the new 3Dimensions mammography system, which is designed to be the fastest, highest resolution breast tomosynthesis system ever, with the 'Intelligent 2D imaging technology'. The 3Dimensions System offers a variety of features designed to provide superior quality 3D images for radiologists, improved workflow for technologists, and a more comfortable mammography experience, with low-dose options, for patients.
Demonstration at the Radiological Society of North America (RSNA)
Quantra™ Breast Density Assessment Software is one of the several new products that are being demonstrated at Hologic's booth at the 103rd Scientific Assembly and Annual Meeting of the RSNA. The RSNA is an international society of radiologists, medical physicists, and other medical professionals with 55,000 members from over 140 countries.
- At the RSNA, Hologic would host a series of interactive workshops and educational symposia. Out of these, two presentations would specifically address the impact that breast tomosynthesis and breast density assessment software can have on clinicians and women with dense breasts.
- Besides, the Company would also conduct workshops on topics such as contrast-enhanced 2D mammography, advancements in 3D™ Mammography, and 3D™ image-guided biopsy solutions.
- Hologic will also showcase its "New Product Theater," wherein representatives from the Company's screening, interventional, and skeletal teams will present every hour during exhibition times.
- These presentations will feature new products such as Brevera® breast biopsy system with CorLumina® imaging technology, and Fluoroscan® InSight™ FD Mini C-Arm extremities imaging system.
Stock Performance Snapshot
November 27, 2017 - At Monday's closing bell, Hologic's stock slightly dropped 0.24%, ending the trading session at $40.77.
Volume traded for the day: 2.10 million shares.
Stock performance in the last month - up 9.80%; previous three-month period - up 8.75%; past twelve-month period - up 4.38%; and year-to-date - up 1.62%
After yesterday's close, Hologic's market cap was at $11.24 billion.
Price to Earnings (P/E) ratio was at 15.42.
The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.
Active-Investors ("A-I') produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE, NASDAQ, and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles, and reports covering equities listed on NYSE and NASDAQ, and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list, contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.